The latest example of this trend is Merck KGaA’s impending all-cash acquisition of SpringWorks Therapeutics, valued around ...
Stock analysts at HC Wainwright dropped their FY2024 earnings per share estimates for SpringWorks Therapeutics in a research note issued on Wednesday, February 12th. HC Wainwright analyst R. Burns now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback